Safety, Tolerability and Pharmacokinetics of APX001 Administered Intravenously
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose
(SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects. The
SAD portion of the study will enroll six cohorts of eight healthy subjects per cohort, for a
total of approximately 48 healthy subjects. The MAD portion of the study will enroll four
cohorts of eight healthy subjects per cohort, for a total of approximately 32 healthy
subjects.